PREvention of Post-mastectomy LYMphoceles by PAdding
PRELYMCA
1 other identifier
interventional
120
1 country
3
Brief Summary
Lymphoceles, or seromas, are the most frequent complication following mastectomy and are associated or not with axillary dissection occurring in 10 to 90% of cases. It is defined as the presence of a palpable post operative serous accumulation that is bothersome for the patient and requires a puncture and drainage or even several repeated punctures. The presence of seromas is therefore associated with discomfort and pain. Seromas could also be responsible for increased morbidity due to complications such as infection, suture separating, lymphedema, prolonged of hospital stay, or a delay in initiation of adjunct treatment (e.g. chemotherapy, radiotherapy). Some risk factors have been identified, such as obesity, increased post operative drainage of J1 to J3, and arterial hypertension. Different measures have demonstrated the benefits of limiting axillary lymphoceles after dissection : placement of a drain, padding and delay in shoulder mobility. Studies have shown that axillary padding decreases lymphocele development and shortens the length of hospital stay. Some studies based on padding of the mastectomy site also have shown a decrease in post operative seromas; however no study has been done on the usefulness of padding in the mastectomy site alone because they include both padding and a drain or padding of the axillary area. The padding technique the investigators employ is performed at the donor site in breast reconstruction by latissimus dorsi muscle flap, demonstrating a reduction in the rate of seromas. In this study, the classic technique will be compared to padding in the mastectomy site with short drainage (48h).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started May 2013
Longer than P75 for not_applicable
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2013
CompletedFirst Submitted
Initial submission to the registry
September 5, 2016
CompletedFirst Posted
Study publicly available on registry
September 9, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2017
CompletedSeptember 9, 2016
September 1, 2016
4.3 years
September 5, 2016
September 5, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
postoperative lymphoceles
presence or absence of postoperative lymphoceles
Day 15
Study Arms (2)
classic closure
ACTIVE COMPARATORmastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
padding
EXPERIMENTALareas of padding and stiching between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h.
Interventions
mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
areas of padding and running sutures between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h
Eligibility Criteria
You may qualify if:
- Age ≥ 18 years
- Female gender
- Patients with infiltrating or in situ breast cancer
- Indication of surgical treatment by mastectomy
- Patient providing written informed consent
- Patient with health insurance coverage
- Ability to provide voluntary written informed consent
You may not qualify if:
- Informed consent cannot be obtain
- Pregnant or lactating women
- Patients undergoing immediate breast reconstruction
- Patients with cancer untreatable by mastectomy, non curative mastectomy: partial mastectomies, preventive mastectomies (BRCA genetic mutations)
- Patients under legal protection or unable to come to a center
- Patients unable to express voluntary consent
- Patients receiving post operative anticoagulants or platelet antiaggregants
- Patients requiring postoperative anticoagulants
- Bilateral mastectomy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
CHU Amiens
Amiens, 80054, France
CH Compiègne
Compiègne, 60321, France
CH Soissons
Soissons, 02209, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 5, 2016
First Posted
September 9, 2016
Study Start
May 1, 2013
Primary Completion
August 1, 2017
Study Completion
August 1, 2017
Last Updated
September 9, 2016
Record last verified: 2016-09